Only China locations: Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patients: the POSEIDON Trial

Inclusion criteria: 18 Years and older. Advanced non-squamous non-small cell lung cancer (NSCLC). RET fusion positive.

Sponsor/Collaborator: Hunan Province Tumor Hospital

Contact and Locations:
Name: Yongchang Zhang, MD
Phone Number: +8613873123436 ext 7+861383123436
Email: zhangyongchang@csu.edu.cn

Mechanism of action: PD-1 antibody: A monoclonal antibody directed against the cell surface receptor PD-1 with potential anti-neoplastic effects by restoring immune function through the activation of T-cells.

Phases: Observational

NCT Number: NCT04322591

URL: https://www.clinicaltrials.gov/study/NCT04322591

Status: Recruiting